PuSH - Publikationsserver des Helmholtz Zentrums München

Habermehl, D.* ; Kessel, K.* ; Welzel, T.* ; Hof, H.* ; Abdollahi, A.* ; Bergmann, F.* ; Rieken, S.* ; Weitz, J.* ; Werner, J.* ; Schirmacher, P.* ; Büchler, M.W.* ; Debus, J.* ; Combs, S.E.*

Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer.

Radiat. Oncol. 7:28 (2012)
DOI PMC Verlagsversion bestellen
Open Access Gold möglich sobald Verlagsversion bei der ZB eingereicht worden ist.
INTRODUCTION: To evaluate efficacy and secondary resectability in patients with locally advanced pancreatic cancer (LAPC) treated with neoadjuvant chemoradiotherapy (CRT). PATIENTS AND METHODS: A total of 215 patients with locally advanced pancreatic cancer were treated with chemoradiation at a single institution. Radiotherapy was delivered with a median dose of 52.2 Gy in single fractions of 1.8 Gy. Chemotherapy was applied concomitantly as gemcitabine (GEM) at a dose of 300 mg/m2 weekly, followed by adjuvant cycles of full-dose GEM (1000 mg/m2). After neoadjuvant CRT restaging was done to evaluate secondary resectability. Overall and disease-free survival were calculated and prognostic factors were estimated. RESULTS: After CRT a total of 26% of all patients with primary unresectable LAPC were chosen to undergo secondary resection. Tumour free resection margins could be achieved in 39.2% (R0-resection), R1-resections were seen in 41.2%, residual macroscopic tumour in 11.8% (R2) and in 7.8% resection were classified as Rx. Patients with complete resection after CRT showed a significantly increased median overall survival (OS) with 22.1 compared to 11.9 months in non-resected patients. Median OS and disease-free survival (DFS) of all patients were 12.3 and 8.1 months respectively. In most cases the first site of disease progression was systemic with hepatic (52%) and peritoneal (36%) metastases. DISCUSSION: A high percentage of patients with locally advanced pancreatic cancer can undergo secondary resection after gemcitabine-based chemoradiation and has a relative long-term prognosis after complete resection.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
ISSN (print) / ISBN 1748-717X
e-ISSN 1748-717X
Zeitschrift Radiation Oncology
Quellenangaben Band: 7, Heft: , Seiten: , Artikelnummer: 28 Supplement: ,
Verlag BioMed Central
Begutachtungsstatus
Institut(e) Institute for Pancreatic Beta Cell Research (IPI)